PMID- 29381772
OWN - NLM
STAT- MEDLINE
DCOM- 20180309
LR  - 20220408
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 13
IP  - 1
DP  - 2018
TI  - Comparison of outcomes in hematological malignancies treated with haploidentical 
      or HLA-identical sibling hematopoietic stem cell transplantation following 
      myeloablative conditioning: A meta-analysis.
PG  - e0191955
LID - 10.1371/journal.pone.0191955 [doi]
LID - e0191955
AB  - PURPOSE: Haploidentical and human leukocyte antigen (HLA)-identical sibling 
      hematopoietic stem transplantation are two main ways used in allogeneic 
      hematopoietic stem cell transplantation (allo-HSCT). In recent years, remarkable 
      progress has been made in haploidentical allo-HSCT (HID-SCT), and some 
      institutions found HID-SCT had similar outcomes as HLA-identical sibling 
      allo-HSCT (ISD-SCT). To clarify if HID-SCT has equal effects to ISD-SCT in 
      hematologic malignancies, we performed this meta-analysis. METHODS: Relevant 
      articles published prior to February 2017 were searched on PubMed. Two reviewers 
      assessed the quality of the included studies and extracted data independently. 
      Odds ratio (OR) and 95% confidence intervals (CIs) were calculated for 
      statistical analysis. RESULTS: Seven studies including 1919 patients were 
      included. The rate of platelet engraftment is significantly lower after HID-SCT 
      versus ISD-SCT while there is no difference in neutrophil engraftment (OR = 2.58, 
      95% CI = 1.70-3.93, P < 0.00001). The risk of acute graft-versus-host disease 
      (GVHD) is significantly higher after HID-SCT versus ISD-SCT (OR = 1.88, 95% CI = 
      1.42-2.49, P < 0.00001), but the relapse rate is lower in HID-SCT group (OR = 
      0.70, 95% CI = 0.55-0.90, P = 0.005). The incidence rates of overall survival 
      (OS) and disease-free-survival/leukemia-free survival/relapse-free survival 
      (DFS/LFS/RFS) after ISD-SCT are all significantly superior to HID-SCT (OR = 1.32, 
      95% CI = 1.08-1.62, P = 0.006; OR = 1.25, 95% CI = 1.03-1.52, P = 0.02). There is 
      no significant difference in transplantation related mortality (TRM) rate after 
      HID-SCT and ISD-SCT. CONCLUSION: After myeloablative conditioning, patients 
      receiving ISD-SCT have a faster engraftment, lower acute GVHD and longer life 
      expectancy compared to HID-SCT with GVHD prophylaxis (cyclosporine A, 
      methotrexate, mycophenolate mofetil and antithymoglobulin; CsA + MTX + MMF + 
      ATG). Currently, HID-SCT with GVHD prophylaxis (CsA + MTX + MMF + ATG) may not 
      replace ISD-SCT when HLA-identical sibling donor available.
FAU - Chen, Dangui
AU  - Chen D
AUID- ORCID: 0000-0003-3424-0718
AD  - Department of Hematology, Nanjing Drum Tower Hospital Clinical College of Nanjing 
      Medical University, Nanjing, People's Republic of China.
FAU - Zhou, Di
AU  - Zhou D
AD  - Department of Hematology, Nanjing Drum Tower Hospital, The Affiliated Hospital of 
      Nanjing University Medical School, Gulou district, Nanjing, People's Republic of 
      China.
FAU - Guo, Dan
AU  - Guo D
AD  - Department of Hematology, Nanjing Drum Tower Hospital Clinical College of Nanjing 
      Medical University, Nanjing, People's Republic of China.
FAU - Xu, Peipei
AU  - Xu P
AD  - Department of Hematology, Nanjing Drum Tower Hospital, The Affiliated Hospital of 
      Nanjing University Medical School, Gulou district, Nanjing, People's Republic of 
      China.
FAU - Chen, Bing
AU  - Chen B
AD  - Department of Hematology, Nanjing Drum Tower Hospital Clinical College of Nanjing 
      Medical University, Nanjing, People's Republic of China.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
DEP - 20180130
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
RN  - 0 (HLA Antigens)
SB  - IM
MH  - HLA Antigens/immunology
MH  - Haplotypes
MH  - Hematologic Diseases/*therapy
MH  - Hematopoietic Stem Cell Transplantation
MH  - Humans
MH  - Survival Analysis
MH  - *Transplantation Conditioning
PMC - PMC5790250
COIS- Competing Interests: The authors have declared that no competing interests exist.
EDAT- 2018/01/31 06:00
MHDA- 2018/03/10 06:00
PMCR- 2018/01/30
CRDT- 2018/01/31 06:00
PHST- 2017/06/04 00:00 [received]
PHST- 2018/01/15 00:00 [accepted]
PHST- 2018/01/31 06:00 [entrez]
PHST- 2018/01/31 06:00 [pubmed]
PHST- 2018/03/10 06:00 [medline]
PHST- 2018/01/30 00:00 [pmc-release]
AID - PONE-D-17-21338 [pii]
AID - 10.1371/journal.pone.0191955 [doi]
PST - epublish
SO  - PLoS One. 2018 Jan 30;13(1):e0191955. doi: 10.1371/journal.pone.0191955. 
      eCollection 2018.